Stem cell therapy for chronic heart failure

Current Opinion in Cardiology

Volumn 30, Issue 3, 2015, Pages 301-310

  Poglajen, Gregor ^a   Vrtovec, Bojan ^a,b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dilated cardiomyopathy; heart failure; ischemic cardiomyopathy; stem cells

Indexed keywords

BONE MARROW CELL; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW DERIVED STEM CELL; CARDIAC STEM CELL; CARDIOSPHERE DERIVED CELL; CLINICAL TRIAL (TOPIC); FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART PERFORMANCE; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; MYOBLAST; MYOTUBE; OXYGEN CONSUMPTION; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL MUSCLE SATELLITE CELL; STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CYTOLOGY; HEART MUSCLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; STEM CELL; TRANSPLANTATION;

BONE MARROW TRANSPLANTATION; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOBLASTS, SKELETAL; MYOCARDIUM; PATIENT SELECTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84928564312     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000167     Document Type: Review

References (51)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012; 125:e2-e220.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147-e239.
3. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410:701-705.
4. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105:829-841.
5. Menasche P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200.
6. Dib N, Dinsmore J, Lababidi Z, et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAUSMIC study). JACC Cardiovasc Interv 2009; 2:9-16
7. Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: The SEISMIC trial. EuroIntervention 2011; 6:805-812.
8. Assmus B, Fischer-Rasokat U, Honold J, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res 2007; 100:1234-1241.
9. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 2006; 114:I101-107.
10. Yao K, Huang R, Qian J, et al. Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart 2008; 94:1147-1153.
11. Perin EC, Silva GV, Henry TD, et al. A randomized study of transendocardial injectionofautologousbonemarrowmononuclearcellsandcell functionanalysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011; 161:1078-1087.
12. Ang KL, Chin D, Leyva F, et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med 2008; 5:663-670.
13. Patel AN, Geffner L, Vina RF, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thorac Cardiovasc Surg 2005; 130:1631-1638.
14. Perin EC, Silva GV, Zheng Y, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012; 163:415-421.
15. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012; 308:2369-2379.
16. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378:1847-1857.
17. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379:895-904.
18. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014; 311:62-73.
19. Nasseri BA, Ebell W, DandelM, et al. Autologous CD133bonemarrowcells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial. Eur Heart J 2014; 35:1263-1274.
20. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res 2014; 114:1302-1310.
21. Perin EC, Sanz-Ruiz R, Sánchez PL, et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 2014; 168:88-95.
22. Poglajen G, Sever M, Cukjati M, et al. Effects of transendocardial CD34 cell transplantation in patients with ischemic cardiomyopathy. Circ Cardiovasc Interv 2014; 7:552-559.
23. Seth S, Narang R, Bhargava B, et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: The first-in-man ABCD (autologous bone marrow cells in dilated cardiomyopathy) trial. J Am Coll Cardiol 2006; 48:2350-2351.
24. Vrtovec B, Poglajen G, Lezaic L, et al. Effects of intracoronary CD34 stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013; 112:165-173.
25. Fischer-Rasokat U, Assmus B, Seeger FH, et al. A pilot trial to assess potential effects of selective intracoronary bonemarrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ Heart Fail 2009; 2:417-423.
26. Farahmand P, Lai TY, Weisel RD, et al. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation 2008; 118:S130-S137.
27. Bonaros N, Rauf R, Wolf D, et al. Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure. J Thorac Cardiovasc Surg 2006; 132:1321-1328.
28. Siminiak T, Fiszer D, Jerzykowska O, et al. Percutaneous trans-coronaryvenous transplantation of autologous skeletal myoblasts in the treatment of postinfarction myocardial contractility impairment: The POZNAN trial. Eur Heart J 2005; 26:1188-1195.
29. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107:2294-2302.
30. Perin EC, Dohmann HF, Borojevic R, et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110:II213-II218.
31. Galinanes M, Loubani M, Davies J, et al. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant 2004; 13:7-13.
32. Beeres SL, Bax JJ, Dibbets-Schneider P, et al. Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am J Cardiol 2007; 100:1094-1098.
33. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355:1222-1232.
34. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRNtrial. JAMA 2012; 307:1717-1726.
35. Bocchi EA, Bacal F, Guimarães G, et al. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int J Cardiol 2010; 138:94-97.
36. Rehman J, Li J, Orschell CM, March KL. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107:1164-1169.
37. Vrtovec B, Poglajen G, Sever M, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 2011; 17:272-281.
38. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105:93-98.
39. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109:337-346.
40. Suncion VY, Ghersin E, Fishman JE, et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res 2014; 114:1292-1301.
41. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology. Circ Res 2011; 109:941-961.
42. Linke A, Muller P, Nurzynska D, et al. Stem cells in the dogheart are selfrenewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A 2005; 102:8966-8971.
43. Fischer KM, Cottage CT, Wu W, et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing pim-1 kinase. Circulation 2009; 120:2077-2087.
44. Angert D, Berretta RM, Kubo H, et al. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res 2011; 108:1226-1237.
45. Bolli R, Tang XL, Sanganalmath SK, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013; 128:122-131.
46. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004; 95:911-921.
47. Johnston PV, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009; 120:1075-1083.
48. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006; 116:1865-1877.
49. Theiss HD, David R, Engelmann MG, et al. Circulation of CD34 progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM). Eur Heart J 2007; 28:1258-1264.
50. Sheng CC, Zhou L, Hao J. Current stem cell delivery methods for myocardial repair. BioMed Res Int 2013; 2013:547902.
51. Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34 cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013; 128 (11 Suppl 1):S42-S49.